Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$12.78 USD
-0.22 (-1.69%)
Updated May 20, 2024 04:00 PM ET
After-Market: $12.76 -0.02 (-0.16%) 5:32 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 181 - 189 ( 189 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
RPL554 is Winning the Clinical Beauty Contest in COPD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
We reiterate our OUTPERFORM rating and a 12-month price target of $25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Initiating with an OUTPERFORM and $25 PT; RPL554: A First-in-Class, Dual-Action Inhibitor for the Treatment of Serious Lung Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Initiating with an OUTPERFORM and $25 PT; RPL554: A First-in-Class, Dual-Action Inhibitor for the Treatment of Serious Lung Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L